Artelo Biosciences completes 1-for-3 reverse split; FY2025 net loss $12.9M, going concern

ARTELO BIOSCIENCES, INC.

1-for-3 reverse stock split effective March 10, 2026; shares reduced from 2.1M to ~708k.
FY2025 net loss of $12.9M, up from $9.8M in FY2024; accumulated deficit reaches $63M.
Cash and cash equivalents of $0.6M at Dec 2025; auditor includes going concern qualification.
Loss on debt extinguishment totaled $1.158M ($825k + $333k related party) in FY2025.
Convertible notes issued at 12% interest; total convertible debt of $609k at Dec 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.